Clopidogrel is a favourable alternative to ticagrelor in older patients with NSTE-ACS

Affiliations

Comment

Karina Huynh. Nat Rev Cardiol. 2020 Jul.

. 2020 Jul;17(7):384.

doi: 10.1038/s41569-020-0393-9.

No abstract available

Comment on

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Gimbel M, et al. Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1. Lancet. 2020. PMID: 32334703 Clinical Trial.

1. Gimbel, M. et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 395, 1374–1381 (2020) - DOI